Gynecologic Cancer
From the Journals
Decreased incidence, survival in low-grade serous ovarian cancer illustrate ‘diagnostic shift’
Relative to serous borderline ovarian tumors, low-grade serous ovarian cancer cases declined precipitously through 2000, with a trend toward...
From the Journals
Sharp declines for lung cancer, melanoma deaths fuel record drop in cancer mortality
Reductions in smoking are largely responsible for the lung cancer progress, while immunotherapy and targeted treatments have improved survival in...
Conference Coverage
Pelvic insufficiency fractures are common after chemoradiotherapy for cervical cancer
CHICAGO – Fractures were more common than previously thought, and many were slow to heal.
From the Journals
Fertility-sparing surgery is safe for most with epithelial ovarian cancer
Except among women with advanced serous tumors, surgery preserving the unaffected ovary and uterus was not associated with a significantly...
From the Journals
Sequential CRT, immunotherapy nets high PFS in node-positive cervical cancer
More than four in five patients were alive and free of disease progression a year after receiving chemoradiotherapy followed by ipilimumab, and...
Opinion
How should we monitor for ovarian cancer recurrence?
Tumor marker assessment in the surveillance period may be more of a hindrance than a help.
From the Journals
In recurrent ovarian cancer, secondary surgery does not extend survival
Longer-than-expected survival times and substantial platinum sensitivity among women in the trial could have diluted an independent surgical...
Conference Coverage
Surgical staging improves cervical cancer outcomes
VANCOUVER – Surgical staging outperforms CT scans, but a key question remains.
From the Journals
Sentinel node biopsy safe for women with vulval cancer
Sentinel node biopsy in women with vulval cancer could identify those at a low risk of recurrence.
Conference Coverage
Molecule exhibits activity in heavily pretreated, HER2-positive solid tumors
NATIONAL HARBOR, MD – In a phase 1 trial of 18 evaluable patients, PRS-343, a 4-1BB/HER2 bispecific molecule,...
Opinion
Disparity in endometrial cancer outcomes: What can we do?
Black women report symptoms less, have more delays in diagnosis, and experience more frequent deviations from guideline-directed diagnostics.